UK: Automation of Supply Chain Cell and Gene Therapy: UKRI Grants Loan to Expedite Digitization of Batch Verification
Developer of manufacturing systems for cell and gene therapies, Autolomous, has received a loan from UK Research and Innovation (UKRI), the public innovation agency, as part of the medicine’s manufacturing challenge.
London/UK — Innovate UK (UKRI) drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. UKRI is part of UK Research and Innovation. By granting a loan to Autolomous, the organization wants to expedite the development of a critical part of their end to end solution for cell and gene therapy manufacturers. The solution is to provide this sector with critically-needed automation in the supply chain, supporting a safe and controlled delivery of more therapies to more patients
The loan is provided as additional support for Autolomous to expedite development of Autolo Mate-Assist, its digital batch verification technology for cell and gene therapies (CGT). The project has commenced in April 2021 and is expected to last 24 months.
Autolo Mate-Assist is the third module from Autolomous’ digital platform Autolo Mate. This is a business critical robust digital platform for efficiency, scalability and process streamlining of the GMP manufacturing and batch verification of cell & gene therapies. The other Autolo Mate modules are Autolo Mate-eBMR, which digitizes batch manufacturing records, and Autolo Mate-Clock that provides complete scheduling of all critical manufacturing variables. The three modules of the Autolo Mate platform will enable manufacturers of advanced therapies and cell and gene therapies to develop an end to end manufacturing strategy.
The system will be the first digital batch verification solution available to the market which will be fully integrated with both an electronic batch manufacturing record solution (eBMR), Autolo Mate-eBMR, and scheduling capability, Autolo Mate-Clock. The completion of a digital batch verification solution will be critical for the scale up of cell and gene and advanced therapies. Currently, paper based batch verification is providing one of the most significant bottlenecks in the cell and gene therapy manufacturing sector. This will increase in intensity as the industry continues to scale. The alleviation of this bottleneck will be absolutely critical as more advanced therapies progress through clinical stages into commercialization.